This site is intended for healthcare professionals

Rinvoq is filed in Japan to treat non-radiographic axial spondyloarthritis .- AbbVie

Read time: 1 mins
Published:17th Mar 2022

Abbvie has filed its JAK inhibitor Rinvoq (upadacitinib) in Japan for an additional indication of non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients who have responded inadequately to existing treatments.


This submission is supported by data from a multinational Phase III clinical study, including Japan evaluating the drug in adult patients with active nr-axSpA with objective signs of inflammation who had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs), or intolerance to or contraindication for NSAIDs.

Rinvoq is already approved in Japan for the treatment of rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.

Condition: Axial Spondyloarthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.